Latent autoimmune diabetes in adults: Definition, prevalence, β-cell function, and treatment

Diabetes

Volumn 54, Issue SUPPL. 2, 2005, Pages

  Stenström, Gunnar ^a   Gottsäter, Anders ^b   Bakhtadze, Ekaterine ^b   Berger, Bo ^b   Sundkvist, Göran ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZOXIDE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCOSE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE ANTIBODY; HEAT SHOCK PROTEIN; INSULIN; METFORMIN; MONOCLONAL ANTIBODY CD3; OCTREOTIDE; PANCREAS ISLET CELL ANTIBODY; PROTEIN DIAPEP277; SULFONYLUREA; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DIABETES IN ADULTS; AUTOIMMUNE DISEASE; CELL DESTRUCTION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC DIET; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; GENOTYPE; HLA SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LATENT AUTOIMMUNE DIABETES IN ADULTS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONSET AGE; PANCREAS FUNCTION; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; BIOLOGICAL MARKERS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GLUCOSE; HUMANS; INSULIN; ISLETS OF LANGERHANS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 33644787064     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.54.suppl_2.S68     Document Type: Article

References (48)

1. Groop LC, Bottazzo GF, Doniac D: Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 35:237-241, 1986
2. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359-362, 1993
3. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA: Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11:299-303, 1994
4. Mølbak AG, Christau B, Marner B, Borch-Johnsen K, Nerup J: Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabet Med 11:650-655, 1994
5. Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, Sugimoto T, Murase T, Kosaka K: Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16:780-788, 1993
6. Lohmann T, Seissler J, Verlohren H-J, Schröder S, Rötger J, Dähn K, Morgenthaler N, Scherbaum WA: Distinct genetic and immunological features in patients with onset of IDDM before and after age 40. Diabetes Care 20:524-529, 1997
7. Seissler J, de Sonnaville JJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, Lan MS, Notkins AL, Heine RJ, Scherbaum WA: Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 41:891-897, 1998
8. Juneja R, Palmer JP: Type 1 1/2 diabetes: myth or reality? Autoimmunity 29:65-83, 1999
9. Lohmann T, Nietzschmann U, Kiess W: "Lady-like": is there a latent autoimmune diabetes in the young? Diabetes Care 23:1707-1708, 2000
10. Pozzilli P, Di Mario U: Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 24:1460-1467, 2001
11. Lohmann T, Kellner K, Verlohren HJ, Krug J, Steindorf J, Scherbaum WA, Seissler J: Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 44:1005-1010, 2001
12. Borg H, Gottsäter A, Landin-Olsson M, Fernlund P, Sundkvist G: High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 86:3032-3038, 2001
13. Hosszufalusi N, Vatay A, Rajczy K, Prohaszka Z, Pozsonyi E, Horvath L, Grosz A, Gero L, Madacsy L, Romics L, Karadi I, Fust G, Panczel P: Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452-457, 2003
14. Palmer JP, Hirsch IB: What's in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 26:536-538, 2003
15. Aycan Z, Berberoglu M, Adiyaman P, Ergur AT, Ensari A, Evliyaoglu O, Siklar Z, Ocal G: Latent autoimmune diabetes mellitus in children (LADC) with autoimmune thyroiditis and Celiac disease. J Pediatr Endocrinol Metab 17:1565-1569, 2004
16. Wroblewski M, Gottsäter A, Lindgärde F, Fernlund P, Sundkvist G: Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40-75 years. Diabetes Care 21:250-255, 1998
17. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157, 1999
18. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R, UK Prospective Diabetes Study (UKPDS) Group: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350:1288-1293, 1997
19. Landin-Olsson M, Karlsson FA, Lernmark Å, Sundkvist G, the Diabetes Incidence Study in Sweden Group: Islet cell and thyrogastric antibodies in 633 consecutive 15-34 yr-old patients in the Diabetes Incidence Study in Sweden. Diabetes 41:1022-1027, 1992
20. Borg H, Arnqvist HJ, Björk E, Bolinder J, Eriksson JW, Nyström L, Jeppsson JO, Sundkvist G: Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adults people (15-34 yrs) in the Diabetes Incidence Study in Sweden (DISS). Diabetologia 46:173-181, 2003
21. Littorin B, Sundkvist G, Hagopian W, Landin-Olsson M, Lernmark Å, Östman J, Arnqvist HJ, Blohmé G, Bolinder J, Eriksson J, Lithner F, Scherstén B, Wibell L: Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment: a cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care 22:409-412, 1999
22. Borg H, Gottsäter A, Fernlund P, Sundkvist G: A 12-year prospective of the relationship between islet antibodies and β-cell function at and after the diagnosis in patients with adult onset diabetes. Diabetes 51:1754-1762, 2002
23. Gottsäter A, Landin-Olsson M, Lernmark Å, Fernlund P, Sundkvist G: Islet cell antibodies are associated with β-cell failure also in obese adult onset diabetic patients. Acta Diabetol 31:226-231, 1994
24. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP: Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 50:1008-1013, 2001
25. Schölin A, Björklund L, Borg H, Arnqvist H, Björk E, Blohmé G, Bolinder J, Eriksson JW, Gudbjörnsdottir S, Nyström L, Östman J, Karlsson AF, Sundkvist G: Islet antibodies and remaining β-cell function eight years after diagnosis of autoimmune diabetes in young adults: a prospective follow-up of the nation-wide Diabetes Incidence Study in Sweden (DISS). J Intern Med 255:384-391, 2004
26. Schölin A, Törn C, Nyström L, Berne C, Arnqvist H, Blohmé G, Bolinder J, Eriksson JW, Kockum I, Landin-Olsson M, Östman J, Sundkvist G, Karlsson AF, Björk E: Normal weight promotes remission and low number of islet antibodies prolong the duration of remission in type 1 diabetes. Diabet Med 21:447-455, 2004
27. Stenström G, Berger B, Borg H, Fernlund P, Dorman JS, Sundkvist G: HLA-DQ genotypes in classical type 1 diabetes and in latent autoimmune diabetes of the adult. Am J Epidem 156:787-796, 2002
28. Li H, Lindholm E, Almgren P, Gustafsson A, Forsblom C, Groop L, Tuomi T: Possible human leukocyte antigen-mediated genetic interaction between type 1 and type 2 diabetes. J Clin Endocrinol Metab 86:574-582, 2001
29. Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio F, Brunetti P, Sanjeevi CB, Falorni A: Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf) 52:565-573, 2000
30. Kucera P, Novakova D, Behanova M, Novak J, Tlaskalova-Hogenova H, Andel M: Gliadin, endomysial and thyroid antibodies in patients with latent autoimmune diabetes of adults (LADA). Clin Exp Immunol 133:139-143, 2003
31. Fourlanos S, Dotta F, Greenbaum CJ, JP P, Harrison LC: Latent autoimmune diabetes in adults should be less latent. Diabetologia. In press
32. Landin-Olsson M, Nilsson KO, Lernmark Å, Sundkvist G: Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 33:561-568, 1990
33. Gottsäter A, Landin-Olsson M, Fernlund P, Gullberg B, Lernmark Å, Sundkvist G: Pancreatic beta-cell function evaluated by intravenous glucose and glucagon stimulation: a comparison between insulin and Cpeptide to measure insulin secretion. Scand J Lab Invest 52:631-639, 1992
34. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark Å, Sundkvist G: Beta-cell function in relation to islet cell antibodies (ICA) during the first three years after the clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16:902-910, 1993
35. Cabrera-Rode E: Prevalence of islet cell antibodies (ICA) in diabetes mellitus and other diseases in Cubans. Autoimmunity 26:7-9, 1997
36. Beales PE, Pozzilli P: Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabete Metab Res Rev 18:114-117, 2002
37. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill V: Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26:2231-2237, 2003
38. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Örn T, Grill V: Effects of insulin vs. glibenclamide in recently diagnosed type 2 diabetic patients (Abstract). Diabetologia 47 (Suppl. 1):A56, 2004
39. Kobayashi T, Nakanishi K, Murase T, Kosaka K: Small dose of subcutaneous insulin as a strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45:622-626, 1996
40. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685-1691, 2002
41. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A, Spera S, Suraci C, Multari G, Cervoni M, Manca Bitti ML, Matteoli MC, Marietti G, Ferrazzoli F, Cassone Faldetta MR, Giordano C, Sbriglia M, Sarugeri E, Ghirlanda G: No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII): IMDIAB Group. Diabetologia 43:1000-1004, 2000
42. Diabetes Prevention Trial-Type 1 Study Group: Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 28:1068-1076, 2005
43. Björk E, Kämpe O, Andersson A, Karlsson FA: Expression of the 64 kDa/glutamic acid decarboxylase rat islet cell autoantigen is influence by the rate of insulin secretion. Diabetologia 32:490-493, 1992
44. Björk E, Berne C, Kämpe O, Wibell L, Oskarsson P, Karlsson FA: Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45:1427-1430, 1996
45. Ortqvist E, Bjork E, Wallensteen M, Ludvigsson J, Aman J, Johansson C, Forsander G, Lindgren F, Berglund L, Bengtsson M, Berne C, Persson B, Karlsson FA: Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 27:2191-2197, 2004
46. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR: Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358:1749-1753, 2001
47. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698, 2002
48. Agardh C-D, Cilio CM, Lethagen A, Lynch K, Leslie RDG, Palmer M, Harris RA, Robertson JA, Lernmark Å: Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19:238-246, 2005